Evercore Forecasts Strong Price Appreciation for Danaher (NYSE:DHR) Stock

Danaher (NYSE:DHR) had its target price hoisted by equities research analysts at Evercore from $225.00 to $232.00 in a report issued on Tuesday,MarketScreener reports. The brokerage presently has an “outperform” rating on the conglomerate’s stock. Evercore’s price target would suggest a potential upside of 19.91% from the stock’s previous close.

A number of other research analysts also recently issued reports on DHR. Wells Fargo & Company reduced their price objective on shares of Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a research report on Wednesday. TD Cowen cut their target price on shares of Danaher from $245.00 to $240.00 and set a “buy” rating on the stock in a research note on Wednesday. Jefferies Financial Group reiterated a “buy” rating and set a $245.00 price target on shares of Danaher in a research report on Tuesday. Argus set a $265.00 price target on shares of Danaher in a research note on Wednesday, January 14th. Finally, The Goldman Sachs Group cut their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Eighteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $241.95.

Danaher Trading Down 0.5%

DHR opened at $193.48 on Tuesday. Danaher has a one year low of $180.03 and a one year high of $242.80. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51. The business has a 50 day simple moving average of $197.89 and a two-hundred day simple moving average of $214.56. The firm has a market capitalization of $136.92 billion, a price-to-earnings ratio of 38.53, a PEG ratio of 2.66 and a beta of 0.95.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same period last year, the company earned $1.88 EPS. The business’s quarterly revenue was up 3.7% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Analysts predict that Danaher will post 8.4 EPS for the current year.

Insider Activity

In related news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the transaction, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. This trade represents a 20.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 10.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Danaher

Institutional investors and hedge funds have recently made changes to their positions in the business. Enterprise Financial Services Corp grew its stake in shares of Danaher by 1.4% in the 4th quarter. Enterprise Financial Services Corp now owns 3,219 shares of the conglomerate’s stock worth $737,000 after buying an additional 46 shares during the last quarter. Kennebec Savings Bank raised its stake in Danaher by 1.4% during the fourth quarter. Kennebec Savings Bank now owns 3,348 shares of the conglomerate’s stock valued at $766,000 after buying an additional 46 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Danaher by 2.6% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,870 shares of the conglomerate’s stock worth $428,000 after acquiring an additional 47 shares in the last quarter. High Note Wealth LLC grew its stake in shares of Danaher by 19.2% in the fourth quarter. High Note Wealth LLC now owns 292 shares of the conglomerate’s stock worth $67,000 after acquiring an additional 47 shares during the last quarter. Finally, First Command Advisory Services Inc. increased its holdings in shares of Danaher by 4.4% during the fourth quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate’s stock valued at $253,000 after acquiring an additional 47 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and guidance lift — Danaher reported $2.06 EPS (above consensus) and raised FY26 EPS guidance to $8.35–8.55, signaling confidence in biotech and life?sciences momentum; this is the main bullish driver. Danaher beats first-quarter profit estimates on strong bioprocessing demand
• Positive Sentiment: Bioprocessing and life?sciences strength — management highlighted double?digit momentum in bioprocessing and continued strength in life?sciences tools, which should support margin expansion and cash generation. Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains
• Neutral Sentiment: Investor materials and transcripts available — the company posted a press release, slide deck and a full earnings?call transcript; useful for modeling segment trends and the acquisition roadmap but no immediate surprise. View Press Release / Slide Deck
• Neutral Sentiment: Strategic M&A focus — coverage notes Danaher’s acquisition strategy (including the Masimo-related work) as an important growth lever; strategic but timing and integration risk remain to be tracked. DHR Q1 deep dive: Bioprocessing momentum and acquisition strategy drive mixed start to 2026
• Negative Sentiment: Revenue slightly missed estimates — Q1 revenue was $5.95B vs. ~ $6.0B consensus, and that shortfall was cited as a reason for near?term share weakness. Danaher (NYSE:DHR) Misses Q1 CY2026 Revenue Estimates
• Negative Sentiment: Diagnostics and respiratory softness — multiple reports flagged weakness in diagnostics and a lowered respiratory outlook, which could pressure near?term organic growth until end markets recover. Danaher Q1 Earnings Beat Estimates, But Revenue Miss, Weak Diagnostics Weigh On Stock

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.